Paul L. Nguyen, MD
Assistant Professor, Department of Radiation Oncology, Harvard Medical School
Director of Prostate Brachytherapy and Clinical Trials for Genitourinary Radiation Oncology, Radiation Oncology, Dana-Farber Cancer Institute
Contact Info
Paul Nguyen
Brigham and Women's Hospital
75 Francis Street
Boston, MA, 02115
Mailstop: ASB1- L2
Phone: 617-732-7936
Fax: 617-975-0912
pnguyen@LROC.harvard.edu
Radiation Oncology
Brigham And Women's Hospital
75 Francis Street
Boston, MA, 02115
Phone: 617-732-7936
Fax: 617-975-0912
skoogler@partners.org
Brigham and Women's Hospital
75 Francis Street
Boston, MA, 02115
Mailstop: ASB1- L2
Phone: 617-732-7936
Fax: 617-975-0912
pnguyen@LROC.harvard.edu
Assistant
Sharon KooglerRadiation Oncology
Brigham And Women's Hospital
75 Francis Street
Boston, MA, 02115
Phone: 617-732-7936
Fax: 617-975-0912
skoogler@partners.org
DF/HCC Program Affiliation
Prostate CancerResearch Abstract
My clinical and research focus is personalizing treatment of men with prostate cancer and optimizing their outcomes. The major areas of focus include:1) Optimizing Risk Stratification and Treatment Selection: Working with Dr. Anthony DAmico, I analyze large cross sectional databases to identify risk factors for recurrence, cancer-specific death and all-cause death and to determine which combination of patient, tumor and treatment characteristics would optimize cancer control while minimally impacting health-related quality of life.
2) Technical Innovations in the Delivery of Radiation: Working with Dr. Robert Cormack in physics, collaborators in radiology, and outside collaborators in engineering, we seek to reduce the side-effects of prostate brachytherapy by using additional imaging and novel devices to decrease the dose delivered to the urethra and rectum.
3) Translational/Genetic Research: Using archived prostate tissue at the DFCI/BWH and the Harvard School of Public Health, we are identifying biomarkers for prostate cancer recurrence and molecular pathways that can potentially be targeted to minimize the risk of recurrence. This work is being done with Dr. Philip Kantoff and in collaboration with Dr. Massimo Loda of molecular pathology and Dr. Jing Ma of the HSPH. In addition, I have funding from the RTOG to analyze tissue from 2 of their randomized trials in collaboration with Dr. Anthony Zietman of MGH.
